Asieris Pharmaceuticals Revolutionizes Cervical Precancer Treatment with CEVIRA® Approval in China
On March 3, 2026, Asieris Pharmaceuticals, a globally recognized biopharmaceutical firm dedicated to advancements in women's health, proudly announced its flagship product, CEVIRA® (APL-1702), has been granted approval by China's National Medical Products Administration (NMPA). This innovative product stands out as the world's first non-invasive treatment option for cervical intraepithelial neoplasia grade 2 (CIN2), addressing a significant clinical gap during a time when cervical cancer continues to pose a serious global health risk for women.
Cervical cancer has emerged as a leading health concern, particularly in regions like China, where the disease remains prevalent. Recent research highlights that over 700,000 women in the country were diagnosed with high-grade lesions, with cerca 60% classified specifically as CIN2. As screening rates are anticipated to rise over the next decade, the demand for effective non-surgical treatments has never been greater. Previous clinical guidelines have gradually transitioned from prioritizing surgical interventions to embracing a more conservative, personalized approach, marking a promising shift in treatment paradigms.
CEVIRA® provides a revolutionary alternative to the surgical methods that have dominated the field, paving the way for a treatment regime that emphasizes non-invasive options. Its approval signals a critical evolution in therapeutic strategies, moving from a standardized 'one-size-fits-all' model to a solution that caters to individual patient needs, and thereby supporting women's health on a broader scale.
Much of the evidence supporting CEVIRA®’s efficacy stems from an extensive Phase III clinical trial, conducted internationally, comprising over 20% European participants. The results of this pivotal study were published in December 2025 in an esteemed medical journal. Key findings included a response rate of 49.6% in patients undergoing CEVIRA® therapy, starkly contrasting with a mere 22.6% in the placebo cohort. Moreover, notable histopathological regression was observed, where 57.5% of women receiving CEVIRA® returned to normal histology or low-grade lesions within six months of treatment commencement. Such outcomes suggest that 60% of patients can bypass the need for surgical excision after limited treatment courses.
CEVIRA® is administered in a straightforward outpatient setting, eliminating the need for anesthesia and allowing for completion of the process within a succinct ten-minute timeframe. The system enables patients to resume their normal daily activities immediately following treatment, thus enhancing both convenience and access to care. Clinical data suggest a remarkable comfort level as well, with approximately 97% of participants reporting no pain during the procedure and no adverse structural damage to the cervix.
Dr. Wei Lihui commented on the approval’s implications for patient care: CEVIRA® is a game changer in conservative cervical cancer management. It offers clinicians an effective and safe intervention method, fostering a new model for treatment while ensuring patients' fertility preservation.
Progressing beyond China, Asieris is also advancing its international ambitions. Currently, an application for marketing authorization for CEVIRA® has been submitted to the European Medicines Agency (EMA), with plans to meet FDA requirements for further post-marketing studies in the United States. Asieris is actively pursuing commercial partnerships globally to bring this innovative therapy to more patients in need.
CEO Dr. Kevin Pan expressed optimism regarding the approval, viewing it not merely as a milestone for Asieris but as a transformative achievement for women’s health globally. Fueled by a commitment to patient-centric solutions, the company is steadfast in its mission to enhance the accessibility and affordability of healthcare innovations, thus improving overall patient outcomes around the world.
The approval of CEVIRA® marks a pivotal moment not only for Asieris but also for women's health advancement, heralding an era of non-invasive treatment strategies that prioritize both efficacy and the quality of patient care.
Cervical cancer has emerged as a leading health concern, particularly in regions like China, where the disease remains prevalent. Recent research highlights that over 700,000 women in the country were diagnosed with high-grade lesions, with cerca 60% classified specifically as CIN2. As screening rates are anticipated to rise over the next decade, the demand for effective non-surgical treatments has never been greater. Previous clinical guidelines have gradually transitioned from prioritizing surgical interventions to embracing a more conservative, personalized approach, marking a promising shift in treatment paradigms.
CEVIRA® provides a revolutionary alternative to the surgical methods that have dominated the field, paving the way for a treatment regime that emphasizes non-invasive options. Its approval signals a critical evolution in therapeutic strategies, moving from a standardized 'one-size-fits-all' model to a solution that caters to individual patient needs, and thereby supporting women's health on a broader scale.
Much of the evidence supporting CEVIRA®’s efficacy stems from an extensive Phase III clinical trial, conducted internationally, comprising over 20% European participants. The results of this pivotal study were published in December 2025 in an esteemed medical journal. Key findings included a response rate of 49.6% in patients undergoing CEVIRA® therapy, starkly contrasting with a mere 22.6% in the placebo cohort. Moreover, notable histopathological regression was observed, where 57.5% of women receiving CEVIRA® returned to normal histology or low-grade lesions within six months of treatment commencement. Such outcomes suggest that 60% of patients can bypass the need for surgical excision after limited treatment courses.
CEVIRA® is administered in a straightforward outpatient setting, eliminating the need for anesthesia and allowing for completion of the process within a succinct ten-minute timeframe. The system enables patients to resume their normal daily activities immediately following treatment, thus enhancing both convenience and access to care. Clinical data suggest a remarkable comfort level as well, with approximately 97% of participants reporting no pain during the procedure and no adverse structural damage to the cervix.
Dr. Wei Lihui commented on the approval’s implications for patient care: CEVIRA® is a game changer in conservative cervical cancer management. It offers clinicians an effective and safe intervention method, fostering a new model for treatment while ensuring patients' fertility preservation.
Progressing beyond China, Asieris is also advancing its international ambitions. Currently, an application for marketing authorization for CEVIRA® has been submitted to the European Medicines Agency (EMA), with plans to meet FDA requirements for further post-marketing studies in the United States. Asieris is actively pursuing commercial partnerships globally to bring this innovative therapy to more patients in need.
CEO Dr. Kevin Pan expressed optimism regarding the approval, viewing it not merely as a milestone for Asieris but as a transformative achievement for women’s health globally. Fueled by a commitment to patient-centric solutions, the company is steadfast in its mission to enhance the accessibility and affordability of healthcare innovations, thus improving overall patient outcomes around the world.
The approval of CEVIRA® marks a pivotal moment not only for Asieris but also for women's health advancement, heralding an era of non-invasive treatment strategies that prioritize both efficacy and the quality of patient care.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.